Status:
COMPLETED
Cavotricuspid Isthmusblock and Circumferential Pulmonary Vein Isolation in Patients With Atrial Fibrillation
Lead Sponsor:
University of Aarhus
Collaborating Sponsors:
Danish Heart Foundation
H. Lundbeck A/S
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
Atrial fibrillation (AF) is the most common cardiac arrhythmia. Pulmonary vein isolation (PVI) in the left atrium using radiofrequency energy is a new and promising non-medical treatment in patients w...
Detailed Description
BACKGROUND: Atrial fibrillation (AF) is the most common cardiac arrhythmia. Medical treatment is often inefficient or associated with side effects. Pulmonary vein isolation (PVI) in the left atrium u...
Eligibility Criteria
Inclusion
- Documented symptomatic paroxysmal or persistent atrial fibrillation where medical treatment has proven inefficient or related to sideeffects.
Exclusion
- Prior cavotricuspid isthmus ablation (for atrial flutter) Significant valvular heart disease Congestive heart failure (NYHA class 3-4) Contraindications to antithrombic treatment with Warfarin
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
149 Patients enrolled
Trial Details
Trial ID
NCT00247780
Start Date
November 1 2004
End Date
October 1 2007
Last Update
February 18 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Cardiology, Skejby University Hospital
Aarhus, Aarhus, Denmark, 8200